Examkin

Soru

Zorluk: Çok zorPulmonary and Critical Care

A 3232-year-old woman with no significant past medical history presents with a 66-month history of progressive exertional dyspnea, atypical chest pain, and near-syncope during exercise. Vital signs are within normal limits. Physical examination reveals a prominent 'a' wave in the jugular venous pulse, a loud pulmonic component of the second heart sound (P2P_2), and a right ventricular heave. Lungs are clear to auscultation. An electrocardiogram demonstrates right axis deviation and right ventricular hypertrophy.

Arrange the following diagnostic steps in the most appropriate chronological order according to current guidelines for the evaluation of this patient's suspected condition.

  1. 1Perform transthoracic echocardiography to assess right ventricular systolic pressure and rule out left-sided heart disease.
  2. 2Obtain pulmonary function tests and a high-resolution computed tomography (HRCT) scan to evaluate for underlying parenchymal lung disease.
  3. 3Perform a ventilation-perfusion (V/Q) scan to screen for chronic thromboembolic disease.
  4. 4Perform right heart catheterization to directly measure pulmonary hemodynamics and confirm pre-capillary physiology.
  5. 5Conduct acute vasoreactivity testing with a short-acting pulmonary vasodilator to determine targeted medical therapy.

Cevap

The correct sequence begins with transthoracic echocardiography, followed by pulmonary function tests and HRCT, then a ventilation-perfusion (V/Q) scan, followed by a right heart catheterization, and concludes with acute vasoreactivity testing.
The evaluation of pulmonary hypertension follows a strict stepwise algorithm to categorize the disease into one of the five WHO groups, minimizing unnecessary invasive testing. The initial step is a transthoracic echocardiogram (TTE) to estimate pulmonary pressures and rule out left heart disease (Group 22), which is the most common cause. Once Group 22 is excluded, pulmonary function tests (PFTs) and high-resolution CT (HRCT) are performed to evaluate for underlying lung disease or hypoxemia (Group 33). If these are unrevealing, a ventilation-perfusion (V/Q) scan is required to screen for chronic thromboembolic pulmonary hypertension (Group 44). Only after Groups 22, 33, and 44 have been excluded should the patient undergo an invasive right heart catheterization (RHC) to definitively confirm the diagnosis of pre-capillary pulmonary arterial hypertension (Group 11). Finally, during the RHC, acute vasoreactivity testing is performed to determine if the patient is a candidate for high-dose calcium channel blocker therapy.

Adım Adım Çözüm

1
Recognize the clinical presentation of pulmonary hypertension.
The patient exhibits classic signs of right heart strain (loud P2P_2, RV heave, prominent 'a' wave) and dyspnea, raising high suspicion for pulmonary hypertension.
Identifying the primary syndrome is required to activate the appropriate diagnostic algorithm.
2
Identify the initial screening step.
Transthoracic echocardiography is selected first.
TTE is the most appropriate initial noninvasive test to estimate pulmonary pressures and rule out the most common cause of PH: left heart disease (WHO Group 2).
3
Sequence the remaining noninvasive diagnostic evaluations.
PFTs and HRCT are ordered next, followed by a V/Q scan.
The algorithm dictates ruling out Group 3 (lung diseases) with PFTs/HRCT, followed by screening for Group 4 (CTEPH) with a V/Q scan, before proceeding to invasive procedures.
4
Determine the definitive diagnostic test.
Right heart catheterization is selected.
RHC is required to confirm pre-capillary pulmonary arterial hypertension (Group 1) after secondary causes have been reasonably excluded.
5
Identify the final therapeutic triage step.
Acute vasoreactivity testing is placed last.
This is performed during the RHC strictly for patients confirmed to have idiopathic PAH to assess candidacy for calcium channel blockers.

Anahtar Kavram

The diagnostic algorithm for pulmonary hypertension proceeds sequentially to rule out common causes (WHO Groups 2 and 3) non-invasively, followed by screening for CTEPH (Group 4), and finally utilizing invasive right heart catheterization to confirm Group 1 pulmonary arterial hypertension.
Tahmini Süre:2m 0s
Bu soruyu puanla

Konular

Pulmonary and Critical Care

Bu konudan daha fazla soru